This study evaluates the procedural outcomes and short-term follow-up of the WATCHMAN FLX Pro left atrial appendage occlusion (LAAO) device (Boston Scientific) using the EXPRESS-LAAO protocol at a high-volume center. from Journal of Invasive Cardiology. Atrial Fibrillation left atrial appendage occlusion
1 February 2025 in The American Journal of Cardiology
The authors present a retrospective analysis on left atrial appendage occlusion in patients with heart failure. Original Contribution from Journal of Invasive Cardiology. Atrial Fibrillation left atrial appendage occlusion Heart Failure Stroke
20 June 2026 in Pacing and Clinical Electrophysiology
Secondary mitral regurgitation (sMR) is commonly understood to be secondary to heart failure (HF), left ventricular (LV) dilation, and altered coaptation of the mitral annulus. Three forms of sMR exist: non-ischemic sMR, ischemic sMR, and atrial functional sMR. In the past, there have been limited treatment options for this condition besides medication. Recently, the management of sMR has been revolutionized by the recent advances in percutaneous transcatheter edge-to-edge repair of the mitral valve (m-TEER). However, the major trials investigating this technology have shown that appropriate patient selection is of critical importance to achieve benefit. As such, there is a renewed interest in the accurate diagnosis of sMR. Herein, we review the etiology, management, and diagnosis of sMR in the era m-TEER.
3 November 2026 in Journal of the American Heart Association
Background: To evaluate whether GLP‐1 (glucagon‐like peptide‐1) receptor agonists (GLP‐1RAs), compared with DPP4 (dipeptidyl peptidase‐4) inhibitors or sulfonylureas, are associated with reduced all‐cause mortality or heart failure hospitalizations in patients with obesity and type 2 diabetes, and heart failure with preserved ejection fraction. Methods: PRAISE‐HFpEF (Glucagon‐Like Peptide‐1 Receptor Agonist in Obese Heart Failure With Preserved Ejection Fraction) was a nationwide multicenter cohort study using a new‐user, active‐comparator design within the national Veterans Affairs Health System (170 US hospitals). Adults with type 2 diabetes between January 1, 2000 and December 31, 2021, were identified from centralized electronic health records. Patients with heart failure with preserved ejection fraction and a body mass index ≥30 kg/m 2 were selected using a validated diagnostic algorithm. Exposure was initiation of a GLP‐1RA versus DPP4 inhibitors/sulfonylurea from January 1, 2015 to December 31, 2021. The primary outcome was time to all‐cause mortality or heart failure hospitalization. Inverse probability of treatment weighting based on the propensity score was used to balanced baseline characteristics. Results: Among 179 288 patients with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, 1024 GLP‐1RA users and 796 DPP4 inhibitors/sulfonylurea users met inclusion criteria. Over a median follow‐up of 1.5 years, GLP‐1RA use was associated with a lower risk of the primary outcome (adjusted hazard ratio, 0.78 [95% CI, 0.64–0.95], P =0.01). Weight loss was modestly greater with GLP‐1RAs compared with DPP4 inhibitors/sulfonylurea (−12.9% versus −10.1%). Conclusions: Among patients with obese heart failure with preserved ejection fraction and type 2 diabetes, GLP‐1RA initiation was associated with a lower incidence of death or heart failure hospitalization compared with alternative oral agents.